483
Astellas Pharma Inc.Astellas Pharma Inc. – FDA 483, Jun 6, 2025
Record Details
Astellas Pharma Inc., a drug substance manufacturer in Takahagi, Japan, was cited for two observations during an FDA inspection. The firm's Quality Unit responsibilities were not fully documented, specifically lacking a control strategy for potential impurities in drug substance. Additionally, computerized systems used for particle size distribution lacked sufficient controls to prevent unauthorized data changes, including deletable raw data and absent audit trails for deletions.
View Company Profile
ID · 32a3ab54-7cab-4e92-8a35-8eeb9b7b1d92
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.